Literature DB >> 25452034

Predonation health-related quality of life scores predict time to recovery in hematopoietic stem cell donors.

Annelies Billen1, J Alejandro Madrigal2, Andre Strydom3, Richard M Szydlo4, Galen E Switzer5, Bronwen E Shaw6.   

Abstract

The physical reactions to hematopoietic stem cell donation have been extensively studied, but less is known about factors that predict poorer donation experiences. The aim of this prospective study was to examine demographic and health-related quality of life (HRQOL) factors that might be associated with recovery and side effects. We also described the changes in HRQOL during the donation process. In total, 275 peripheral blood stem cell (PBSC) and 37 bone marrow (BM) consecutive donors completed the SF-36 questionnaire predonation and 4 weeks, and 3 months postdonation. Predonation HRQOL markers were the strongest predictors of time to recovery. Poorer predonation physical health was associated with longer recovery (P = .017) and certain side effects in PBSC donors. Poorer predonation mental health was associated with longer recovery in BM donors (P = .03) and pain after PBSC donation (P = .003). Physical HRQOL scores declined significantly from predonation to 4 weeks postdonation. This was shown both for PBSC and BM donors (P < .001 and P = .009, respectively), but the decline was much greater for BM donors. There was a return to predonation HRQOL values 3 months after donation in both groups with values well above the mean of the general population (P < .001).
Copyright © 2015 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Bone marrow; Donation experience; Health-related quality of life; Peripheral blood stem cells

Mesh:

Year:  2014        PMID: 25452034     DOI: 10.1016/j.bbmt.2014.10.028

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  5 in total

Review 1.  G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept.

Authors:  U Deotare; G Al-Dawsari; S Couban; J H Lipton
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

2.  Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation.

Authors:  M H Lee; J H Jang; H J Min; H I Jang; J H Nah; C J Lyu; K-S Han; J H Won; Y-H Lee; S Y Chong; Y C Mun; W S Lee; S J Kim; I Kim
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

3.  Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201.

Authors:  Linda J Burns; Brent R Logan; Pintip Chitphakdithai; John P Miller; Rebecca Drexler; Stephen Spellman; Galen E Switzer; John R Wingard; Claudio Anasetti; Dennis L Confer
Journal:  Biol Blood Marrow Transplant       Date:  2016-03-21       Impact factor: 5.742

4.  The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials.

Authors:  Nosha Farhadfar; Kwang Woo Ahn; Stephanie Bo-Subait; Brent Logan; Heather E Stefanski; Jack W Hsu; Sandhya Panch; Dennis Confer; Hien Liu; Sherif M Badawy; Amer Beitinjaneh; Miguel A Diaz; Gerhard C Hildebrandt; Amar H Kelkar; Hillard M Lazarus; Hemant S Murthy; Jaime M Preussler; Raquel M Schears; Akshay Sharma; Marjolein van der Poel; Jessica G Bruce; Michael A Pulsipher; Bronwen E Shaw; John R Wingard; Galen E Switzer
Journal:  Transplant Cell Ther       Date:  2022-06-07

5.  Donation of peripheral blood stem cells to unrelated strangers: A thematic analysis.

Authors:  Annelies Billen; J Alejandro Madrigal; Katrina Scior; Bronwen E Shaw; Andre Strydom
Journal:  PLoS One       Date:  2017-10-25       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.